{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:05:00Z","timestamp":1793394300945,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ekir.2022.09.018","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T12:55:28Z","timestamp":1664456128000},"page":"2589-2607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Use of Glucose-Lowering Agents in Diabetes and CKD"],"prefix":"10.1016","volume":"7","author":[{"given":"Radica Z.","family":"Alicic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.09.018_bib1","unstructured":"United States renal data system. 2021 USRDS annual data report. Epidemiology of Kidney Disease in the United States: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases."},{"key":"10.1016\/j.ekir.2022.09.018_bib2","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ekir.2022.09.018_bib3","doi-asserted-by":"crossref","first-page":"672350","DOI":"10.3389\/fendo.2021.672350","article-title":"Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019","volume":"12","author":"Deng","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ekir.2022.09.018_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.09.018_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-015-0204-5","article-title":"Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors","volume":"14","author":"Soriano","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2022.09.018_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamacardio.2017.4228","article-title":"Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial","volume":"3","author":"Scirica","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ekir.2022.09.018_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2215\/CJN.05070511","article-title":"Risks of subsequent hospitalization and death in patients with kidney disease","volume":"7","author":"Daratha","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.09.018_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.09.018_bib10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.kint.2018.11.007","article-title":"Burden, access, and disparities in kidney disease","volume":"95","author":"Crews","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.09.018_bib11","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2022.09.018_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2022.09.018_bib13","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"64","author":"Tuttle","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.09.018_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1172\/JCI118803","article-title":"Contributions of gluconeogenesis to glucose production in the fasted state","volume":"98","author":"Landau","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.09.018_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s001250050745","article-title":"Renal glucose production and utilization: new aspects in humans","volume":"40","author":"Stumvoll","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2022.09.018_bib17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/ki.2010.509","article-title":"Glucose handling by the kidney","volume":"120","author":"Mather","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2022.09.018_bib18","doi-asserted-by":"crossref","first-page":"E419","DOI":"10.1152\/ajpendo.00032.2001","article-title":"Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis","volume":"282","author":"Meyer","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ekir.2022.09.018_bib19","article-title":"Glucose metabolism in the kidney: neurohormonal activation and heart failure development","volume":"9","author":"Gronda","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2022.09.018_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1463-1326.2000.00085.x","article-title":"Physiology of glucose homeostasis","volume":"2","author":"Gerich","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.09.018_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2017.07.033","article-title":"Renal glucose metabolism in normal physiological conditions and in diabetes","volume":"133","author":"Alsahli","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ekir.2022.09.018_bib22","series-title":"Membrane Transport and Metabolism A Symposium","first-page":"439","article-title":"The restrictions on possible mechanisms of intestinal transport of sugars","author":"Miller","year":"1960"},{"key":"10.1016\/j.ekir.2022.09.018_bib23","doi-asserted-by":"crossref","first-page":"15204","DOI":"10.1016\/S0021-9258(17)36592-4","article-title":"Structure of the human Na+\/glucose cotransporter gene SGLT1","volume":"269","author":"Turk","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2022.09.018_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/330379a0","article-title":"Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter","volume":"330","author":"Hediger","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2022.09.018_bib25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0888-7543(89)90333-9","article-title":"Assignment of the human intestinal Na+\/glucose cotransporter gene (SGLT1) to the q11.2----qter region of chromosome 22","volume":"4","author":"Hediger","year":"1989","journal-title":"Genomics"},{"key":"10.1016\/j.ekir.2022.09.018_bib26","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.09.018_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fphar.2014.00274","article-title":"Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans","volume":"5","author":"Lu","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2022.09.018_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ekir.2022.09.018_bib29","doi-asserted-by":"crossref","first-page":"C373","DOI":"10.1152\/ajpcell.00328.2011","article-title":"Structural selectivity of human SGLT inhibitors","volume":"302","author":"Hummel","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.ekir.2022.09.018_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","article-title":"Active sugar transport in health and disease","volume":"261","author":"Wright","year":"2007","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib31","series-title":"Brenner & Rector\u2019s the Kidney","author":"Brenner","year":"2004"},{"key":"10.1016\/j.ekir.2022.09.018_bib32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ekir.2022.09.018_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00252649","article-title":"The effect of insulin on renal sodium metabolism. A review with clinical implications","volume":"21","author":"DeFronzo","year":"1981","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2022.09.018_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.ajkd.2018.03.022","article-title":"SGLT2 Inhibition for the prevention and treatment of diabetic kidney disease: a review","volume":"72","author":"Alicic","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.09.018_bib35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI2415","article-title":"Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus","volume":"102","author":"Meyer","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.09.018_bib36","doi-asserted-by":"crossref","first-page":"E1049","DOI":"10.1152\/ajpendo.00041.2004","article-title":"Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes","volume":"287","author":"Meyer","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ekir.2022.09.018_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","article-title":"Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects","volume":"28","author":"Mogensen","year":"1971","journal-title":"Scand J Clin Lab Investig"},{"key":"10.1016\/j.ekir.2022.09.018_bib38","first-page":"F946","article-title":"Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus","volume":"260","author":"Pollock","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ekir.2022.09.018_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00232-001-0036-y","article-title":"Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat","volume":"182","author":"Vestri","year":"2001","journal-title":"J\u00a0Membr Biol"},{"key":"10.1016\/j.ekir.2022.09.018_bib40","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ekir.2022.09.018_bib41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia","volume":"14","author":"DeFronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.09.018_bib42","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","article-title":"High basolateral glucose increases sodium-glucose cotransporter 2 and reduces Sirtuin-1 in renal tubules through glucose transporter-2 detection [Sci Rep]","volume":"8","author":"Umino","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2022.09.018_bib43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.ekir.2022.09.018_bib44","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.ekir.2022.09.018_bib45","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/ndt\/gfp558","article-title":"Pre-diabetes and arterial stiffness in uraemic patients","volume":"25","author":"Hornum","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.09.018_bib46","doi-asserted-by":"crossref","first-page":"c47","DOI":"10.1159\/000112529","article-title":"Evidence for increased risk of prediabetes in the uremic patient","volume":"108","author":"Eldin","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2022.09.018_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/j.ajkd.2004.09.034","article-title":"Insulin resistance in patients with chronic kidney disease","volume":"45","author":"Kobayashi","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.09.018_bib48","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2215\/CJN.11861111","article-title":"Chronic kidney disease, insulin resistance, and incident diabetes in older adults","volume":"7","author":"Pham","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.09.018_bib49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1172\/JCI110067","article-title":"Insulin resistance in uremia","volume":"67","author":"DeFronzo","year":"1981","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.09.018_bib50","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1681\/ASN.2015070756","article-title":"Impaired glucose and insulin homeostasis in moderate-severe CKD","volume":"27","author":"de Boer","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.09.018_bib51","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1440-1681.2011.05579.x","article-title":"Developmental origins of obesity-related hypertension","volume":"39","author":"Henry","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ekir.2022.09.018_bib52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40292-020-00408-8","article-title":"Insulin resistance the hinge between hypertension and type 2 diabetes","volume":"27","author":"Mancusi","year":"2020","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.ekir.2022.09.018_bib53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF00400725","article-title":"Insulin resistance and hyperinsulinemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity","volume":"38","author":"Eidmak","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2022.09.018_bib54","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/ndt\/gfx050","article-title":"Uremia induces adipose tissue inflammation and muscle mitochondrial dysfunction","volume":"32","author":"Martinez Cantarin","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.09.018_bib55","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1523-1755.2005.00200.x","article-title":"IL-10, IL-6, and TNF-\u03b1: central factors in the altered cytokine network of uremia\u2014the good, the bad, and the ugly","volume":"67","author":"Stenvinkel","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.09.018_bib56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1681\/ASN.2012010047","article-title":"Frailty and protein-energy wasting in elderly patients with end-stage kidney disease","volume":"24","author":"Kim","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.09.018_bib57","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1523-1755.1998.00898.x","article-title":"Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease","volume":"53","author":"Fliser","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.09.018_bib58","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ki.2012.460","article-title":"Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease","volume":"83","author":"Idorn","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.09.018_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0889-8529(18)30391-8","article-title":"Hypoglycemia associated with renal failure","volume":"18","author":"Arem","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ekir.2022.09.018_bib60","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrneph.2015.38","article-title":"Haemodialysis-induced hypolycaemia an glycaemic disarrays","volume":"11","author":"Abe","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2022.09.018_bib61","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/ki.1995.236","article-title":"Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial","volume":"47","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.09.018_bib62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2022.09.018_bib63","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2013.06.020","article-title":"Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis","volume":"63","author":"Hill","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.09.018_bib64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2022.09.018_bib65","first-page":"S83","article-title":"Glycemic targets: standards of Medical Care in Diabetes\u00a0\u22122022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.09.018_bib66","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1210\/endrev\/bnaa017","article-title":"Glycemic monitoring and management in advanced chronic kidney disease","volume":"41","author":"Galindo","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ekir.2022.09.018_bib67","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/ki.2008.25","article-title":"Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis","volume":"73","author":"Peacock","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.09.018_bib68","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/clinchem\/hvab232","article-title":"Glycated albumin and risk of mortality in the US adult population","volume":"68","author":"Rooney","year":"2022","journal-title":"Clin Chem"},{"key":"10.1016\/j.ekir.2022.09.018_bib69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00592-020-01581-x","article-title":"Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker","volume":"58","author":"Copur","year":"2021","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ekir.2022.09.018_bib70","doi-asserted-by":"crossref","first-page":"108502","DOI":"10.1016\/j.diabres.2020.108502","article-title":"Continuous glucose monitoring: the achievement of 100 years of innovation in diabetes technology","volume":"170","author":"Galindo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ekir.2022.09.018_bib71","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2337\/dc18-1581","article-title":"Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring","volume":"41","author":"Bergenstal","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.09.018_bib72","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.09.018_bib73","first-page":"dci220027","article-title":"Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.09.018_bib74","series-title":"Invokana (Canagliflozin)","year":"2020"},{"key":"10.1016\/j.ekir.2022.09.018_bib75","series-title":"Farxiga (dapagliflozin) [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ekir.2022.09.018_bib76","series-title":"Jardiance (Empagliflozin) [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.ekir.2022.09.018_bib77","series-title":"Steglatro (Ertugliflozin) [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ekir.2022.09.018_bib78","series-title":"Trulicity (Dulaglutide) Injection [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ekir.2022.09.018_bib79","series-title":"Byetta (exenatide) injection [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ekir.2022.09.018_bib80","series-title":"Bydureon (exenatide extended-release) injection [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ekir.2022.09.018_bib81","series-title":"Victoza (Liraglutide) Injection [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ekir.2022.09.018_bib82","series-title":"Adlyxin (Lixisenatide) Injection [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ekir.2022.09.018_bib83","series-title":"Ozempic (Semaglutide) Injection [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.ekir.2022.09.018_bib84","series-title":"Rybelsus (Semaglutide) Tablets [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ekir.2022.09.018_bib85","series-title":"Nesina (alogliptin) [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.ekir.2022.09.018_bib86","series-title":"Tradjenta (Linagliptin) [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.ekir.2022.09.018_bib87","series-title":"Onglyza (saxagliptin) [Prescribing Information]","year":"2019"},{"key":"10.1016\/j.ekir.2022.09.018_bib88","series-title":"Januvia (Sitagliptin) [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ekir.2022.09.018_bib89","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1681\/ASN.2016121372","article-title":"Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease","volume":"28","author":"Neumiller","year":"2017","journal-title":"J\u00a0Am Soc Neprhol"},{"key":"10.1016\/j.ekir.2022.09.018_bib90","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.09.018_bib91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ekir.2022.09.018_bib92","series-title":"Glucophage (metformin) [Prescribing Information]","year":"2018"},{"key":"10.1016\/j.ekir.2022.09.018_bib93","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2022.09.018_bib94","first-page":"22","article-title":"Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure","volume":"12","author":"Sampanis","year":"2008","journal-title":"Hippokratia"},{"key":"10.1016\/j.ekir.2022.09.018_bib95","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2042018813501188","article-title":"Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?","volume":"4","author":"Kulozik","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.ekir.2022.09.018_bib96","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40262-013-0113-2","article-title":"Insulin degludec: pharmacokinetics in patients with renal impairment","volume":"53","author":"Kiss","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ekir.2022.09.018_bib97","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.diabres.2017.02.032","article-title":"Consensus statement on insulin therapy in chronic kidney disease","volume":"127","author":"Rajput","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ekir.2022.09.018_bib98","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2022.09.018_bib99","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.09.018_bib100","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diacare.17.9.1026","article-title":"Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans","volume":"17","author":"Rydberg","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.09.018_bib101","series-title":"Actos (Pioglitazone) [Prescribing Information]","year":"2018"},{"key":"10.1016\/j.ekir.2022.09.018_bib102","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/sj.ki.5001620","article-title":"Protection of the kidney by thiazolidinediones: an assessment from bench to bedside","volume":"70","author":"Sarafidis","year":"2006","journal-title":"Kidney Int"},{"issue":"suppl 4","key":"10.1016\/j.ekir.2022.09.018_bib103","first-page":"73","article-title":"Management of drugs affecting blood glucose in diabetic patients with renal failure","volume":"26","author":"Charpentier","year":"2000","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ekir.2022.09.018_bib104","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/dia.2011.0049","article-title":"The contribution of glucose variability to asymptomatic hypoglycemia in patients with type 2 diabetes","volume":"13","author":"Monnier","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.ekir.2022.09.018_bib105","first-page":"30","article-title":"Hemodialysis-induced hypoglycemia in diabetic patients","volume":"54","author":"Jackson","year":"2000","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2022.09.018_bib106","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1744-9987.2007.00491.x","article-title":"Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose","volume":"11","author":"Abe","year":"2007","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ekir.2022.09.018_bib107","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1525-1594.2010.01112.x","article-title":"Characterization of insulin adsorption behavior of dialyzer membranes used in hemodialysis","volume":"35","author":"Abe","year":"2011","journal-title":"Artif Organs"},{"key":"10.1016\/j.ekir.2022.09.018_bib108","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2021.05.023","article-title":"Management of diabetes mellitus in patients with CKD: core curriculum 2022","volume":"79","author":"Hahr","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2022.09.018_bib109","first-page":"S175","article-title":"Chronic kidney disease and risk management: standards of Medical Care in Diabetes\u22122022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2022.09.018_bib110","first-page":"S144","article-title":"Cardiovascular disease and risk management: standards of Medical Care in Diabetes\u00a0\u22122022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.09.018_bib111","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm\u22122020 Executive Summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ekir.2022.09.018_bib112","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib113","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib114","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib115","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib116","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2022.09.018_bib117","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib118","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib121","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.09.018_bib122","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib123","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib124","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib125","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib126","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib127","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ekir.2022.09.018_bib128","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2022.09.018_bib129","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib131","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib132","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.09.018_bib133","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2022.09.018_bib134","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12020-014-0519-0","article-title":"One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study","volume":"50","author":"Zavattaro","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.ekir.2022.09.018_bib135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.09.018_bib136","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib137","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.09.018_bib138","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCRESAHA.121.319874","article-title":"GLP1R attenuates sympathetic response to high glucose via carotid body inhibition","volume":"130","author":"Pauza","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2022.09.018_bib139","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2022.09.018_bib140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126769","article-title":"The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis","volume":"10","author":"Potts","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2022.09.018_bib141","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRARENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.09.018_bib144","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2015-3754","article-title":"Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study","volume":"101","author":"Aroda","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2022.09.018_bib145","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1042\/CS20171298","article-title":"SGLT2 inhibition and kidney protection","volume":"132","author":"Nespoux","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ekir.2022.09.018_bib146","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.09.018_bib147","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.09.018_bib148","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-014-0325-2","article-title":"Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations","volume":"74","author":"Carris","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2022.09.018_bib149","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s13300-017-0277-0","article-title":"Practical approach to initiating SGLT2 inhibitors in type 2 diabetes","volume":"8","author":"Gomez-Peralta","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ekir.2022.09.018_bib150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/j.ackd.2021.02.001","article-title":"Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned","volume":"28","author":"Neumiller","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2022.09.018_bib151","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1093\/ajhp\/zxab271","article-title":"Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: an opportunity for pharmacists","volume":"79","author":"Neumiller","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ekir.2022.09.018_bib152","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492201782X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492201782X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:43:19Z","timestamp":1762832599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492201782X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":148,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S246802492201782X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.09.018","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Glucose-Lowering Agents in Diabetes and CKD","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}